Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis

INTRODUCTION: Adherence to disease-modifying therapies is key for achieving optimal outcomes in multiple sclerosis (MS). Diroximel fumarate (DRF) is an oral fumarate approved for treatment of relapsing forms of MS. It has the same pharmacologically active metabolite as dimethyl fumarate (DMF) and si...

Descripción completa

Detalles Bibliográficos
Autores principales: Lager, Brittney, Liseno, Jacob, Božin, Ivan, England, Sarah M., Shankar, Sai L., Mendoza, Jason P., Lewin, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837354/
https://www.ncbi.nlm.nih.gov/pubmed/36334241
http://dx.doi.org/10.1007/s40120-022-00413-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837354/
https://www.ncbi.nlm.nih.gov/pubmed/36334241
http://dx.doi.org/10.1007/s40120-022-00413-0

Ejemplares similares